Methods for cyclizing synthetic polymers

ABSTRACT

The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D 1 -X (n) -D 2 , where D 1  is a first catalytic domain of an intein; D 2  is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X (n)  is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D 1 -X (n) -D 2  compounds autocatalytically cyclize the X (n)  polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.11/136,806, filed May 24, 2005, which claims the benefit of U.S.Provisional Patent Application No. 60/574,238, filed May 24, 2004, whichare incorporated by reference herein by their entirety.

FIELD OF THE INVENTION

The present invention generally relates to methods and compositions forcyclizing synthetic polymers, e.g., synthetic peptides.

BACKGROUND OF THE INVENTION

Cyclic peptides are conformationally restricted and, as such, exhibitincreased specificity and affinity in binding to other molecules, ascompared to linear peptides. Further, cyclic peptides are thought to bemore stable in cells and on the shelf than linear peptides, and may besmall enough to avoid recognition by host immune system and to cross theplasma membrane of a cell (Schreiber, 2000 Science 287, 1964-1969; Scottet al., 2001 Chem. Biol. 8, 801-815).

These features make cyclic peptides very attractive drugs. Accordingly,there is a great need for new methods for making cyclic peptides,particularly for the manufacture of synthetic cyclic peptides forclinical investigations and therapeutic use, and for the production ofcyclic peptide libraries that can be screened to identify cyclicpeptides with a desired activity.

Current methods for making cyclic peptides, however, generally fail tomeet this need. For example, linear peptides may be cyclized in vitro byreacting the N- and C-termini of a peptide together to form a covalentbond, e.g., a peptide bond, therebetween. Such methods are typicallyinefficient because the ends of a peptide are sterically prevented fromreacting. This problem is particularly exacerbated in cyclizing smallerpeptides, where the ends of the peptide have less choice ofconformational space. Further, cyclic peptides made by cyclizing linearpeptides can be difficult to purify from the linear peptides, and, assuch, such methods sometimes require sophisticated purificationprocedures. Accordingly, it is often difficult to produce and purify acyclic peptide in any useful amount using synthetic chemistry.

Further, while inteins have been used to cyclize peptides in vitro andin vivo, those peptides are typically synthesized in vivo, i.e., byribosomes in a cell. Such cyclic peptides therefore typically containonly genetically-encodable amino acids (i.e., L-amino acids) and, assuch, are limited in their structural diversity. Further, before theiruse, cyclic peptides produced in a cell are typically purified away fromother cellular components before use. Since this is not a trivial task,cyclic peptides made by cells cannot generally be produced in largeamounts, are typically not amenable to typical high throughput,cell-free, screening assays, and may not be suitable for many clinicalstudies. In addition, cell-based methods are limited to production ofcyclic polymers that are genetically encodable.

Accordingly, there is still a great need for new methods for producingcyclic peptides. In particular, there is a great need for cell-freesystem methods of producing small cyclic peptides containingnon-genetically encodable amino acids.

This invention meets this need, and others.

LITERATURE

-   Dawson et al. (Annu. Rev. Biochem 2000 69:923-60); Arnold et al.    (Scientific World Journal 2001 1:117); Blaschke et al. (Methods    Enzymol. 328:478-496); Wu et al. (Proc. Natl. Acad. Sci. 1998    95:9226-9231); Derbyshire et al. (Proc. Natl. Acad. Sci. 1998    95:1356-1357); Kinsella et al. (J. Biol. Chem. 2002 277:37512-8) and    Muir et al. (Proc. Natl. Acad. Sci. 1998 95:6705-6710); Published    U.S. Patent Applications 20020151006, 20030013148, 20040014100,    20020192773 and 20020150912; and U.S. Pat. Nos. 5,834,247,    6,307,018, 6,184,344, 6,562,617 and 6,455,247.

SUMMARY OF THE INVENTION

The invention provides methods and compositions for production of acyclic polymer in a cell free system. In general, the methods of theinvention involve ligating first and second recombinant intein domainsto a linear synthetic polymer to form a compound containing thestructure: D₁-X_((n))-D₂, where D₁ is a first catalytic domain of anintein, D₂ is a second catalytic domain of an intein, the secondcatalytic domain has at its N-terminus a first reactive site for theintein and X_((n)) is a polymer of a number n of monomer X, where thepolymer N-terminus has a second reactive site for the intein.D₁-X_((n))-D₂ compounds autocatalytically cyclize the X_((n)) polymer toproduce a cyclic polymer. Libraries of D₁-X_((n))-D₂ compounds can beused in production of libraries of cyclic polymers. The invention findsuse in a variety of drug discovery, clinical and therapeuticapplications.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is best understood from the following detailed descriptionwhen read in conjunction with the accompanying drawings. It isemphasized that, according to common practice, the various features ofthe drawings are not to-scale. On the contrary, the dimensions of thevarious features are arbitrarily expanded or reduced for clarity.Included in the drawings are the following figures:

FIG. 1 is a first schematic representation of an embodiment of theinvention.

FIG. 2 is a second schematic representation of an embodiment of theinvention.

FIGS. 3A-3E show an exemplary method for producing a synthetic cyclicpolymer using an intein.

DEFINITIONS

Before the present invention is further described, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may of course vary. It is also to be understood thatthe terminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting. Unless definedotherwise, all technical and scientific terms used herein have the samemeaning as commonly understood by one of ordinary skill in the art towhich this invention belongs.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges, and are also encompassed within the invention, subjectto any specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Throughout this application, various publications, patents and publishedpatent applications are cited. The disclosures of these publications,patents and published patent applications referenced in this applicationare hereby incorporated by reference in their entirety into the presentdisclosure. Citation herein by Applicant of a publication, patent, orpublished patent application is not an admission by Applicant of saidpublication, patent, or published patent application as prior art.

It must be noted that as used herein and in the appended claims, thesingular forms “a”, “and”, and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “apolypeptide” includes a plurality of such polypeptides, and reference to“the compound” includes reference to one or more compounds andequivalents thereof known to those skilled in the art, and so forth. Itis further noted that the claims may be drafted to exclude any optionalelement. As such, this statement is intended to serve as antecedentbasis for use of such exclusive terminology as “solely”, “only” and thelike in connection with the recitation of claim elements, or the use ofa “negative” limitation.

The term “polymer”, as used herein, refers to a linear or cycliccompound that is made up of a series of monomers or subunits that arecovalently bonded together to form a chain. A polymer may be ahomopolymeric (i.e., may contain monomers that are identical to eachother) or may be a heteropolymeric (i.e., may contain monomers that aredifferent to each other). A polymer may therefore contain two or moredifferent monomers (i.e., monomers that have chemical structures thatare different to each other). In certain embodiments the monomers of apolymer are below about 500 Da in size (e.g., about 50 Da to about 150Da in size).

The term “organic polymer”, as used herein, refers to a polymer thatprimarily contains atoms of carbon (C) and hydrogen (H). Organicpolymers are generally made up of any combination of carbon, nitrogen,oxygen and hydrogen atoms, for example. Exemplary organic polymersinclude plastics (e.g., poly(vinyl chloride), polyacrylate,polyethylene, polypropylene, poly(4-methylbutene), polystyrene,polymethacrylate, poly(ethylene terephthalate), nylon, poly(vinylbutyrate) and epoxy) and biopolymers, e.g., polypeptides (as discussedbelow), nucleic acids, carbohydrates (e.g., cellulose polymers such asnitrocellulose, cellulose acetate, dextran and agarose, etc.), lipids,and molecules containing any mixture of amino acids, nucleotides, sugaror lipid monomers. The chemistry for making organic polymers isgenerally well known in the art.

A “biopolymer” is a polymer containing amino acid and/or nucleotidemonomers, regardless of its source. A biopolymer may benaturally-occurring, obtained from a cell-based recombinant expressionsystem, or synthetic. The term “biopolymer” refers to polypeptides andpolynucleotides and includes compounds containing amino acids,nucleotides, or a mixture thereof.

The terms “polypeptide” and “protein” are used interchangeablythroughout the application and mean at least two covalently attachedamino acids, which includes proteins, polypeptides, oligopeptides andpeptides. A polypeptide may be made up of naturally occurring aminoacids and peptide bonds, synthetic peptidomimetic structures, or amixture thereof. Thus “amino acid”, or “peptide residue”, as used hereinencompasses both naturally occurring and synthetic amino acids andincludes optical isomers of naturally occurring (genetically encodable)amino acids, as well as analogs thereof. For example,homo-phenylalanine, citrulline and noreleucine are considered aminoacids for the purposes of the invention. “Amino acid” also includesimino acid residues such as proline and hydroxyproline. The side chainsmay be in either the D- or the L-configuration. If non-naturallyoccurring side chains are used, non-amino acid substituents may be used,for example to prevent or retard in vivo degradation. The term “aminoacid” encompasses α- and β-amino acids.

In general, polypeptides may be of any length, e.g., greater than 2amino acids, greater than 4 amino acids, greater than about 10 aminoacids, greater than about 20 amino acids, greater than about 50 aminoacids, greater than about 100 amino acids, greater than about 300 aminoacids, usually up to about 500 or 1000 or more amino acids. “Peptides”are generally greater than 2 amino acids, greater than 4 amino acids,greater than about 10 amino acids, greater than about 20 amino acids,usually up to about 10, 20, 30, 40 or 50 amino acids. In certainembodiments, peptides are between, 3 and 5 or 5 and 30 amino acids inlength. In certain embodiments, a peptide may be three or four aminoacids in length.

The term “fusion protein” or grammatical equivalents thereof is meant aprotein composed of a plurality of polypeptide components that whiletypically unjoined in their native state, typically are joined by theirrespective amino and carboxyl termini through a peptide linkage to forma single continuous polypeptide. Fusion proteins may be a combination oftwo, three or even four or more different proteins. The term polypeptideincludes fusion proteins, including, but not limited to, a fusion of twoor more heterologous amino acid sequences, a fusion of a polypeptidewith: a heterologous targeting sequence, a linker, an immunologicallytag, a detectable fusion partner, such as a fluorescent protein,β-galactosidase, luciferase, etc., and the like.

The terms “nucleic acid molecule” and “polynucleotide” are usedinterchangeably and refer to a polymeric form of nucleotides of anylength, either deoxyribonucleotides or ribonucleotides, or analogsthereof. Polynucleotides may have any three-dimensional structure, andmay perform any function, known or unknown. Non-limiting examples ofpolynucleotides include a gene, a gene fragment, exons, introns,messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA,recombinant polynucleotides, branched polynucleotides, plasmids,vectors, isolated DNA of any sequence, control regions, isolated RNA ofany sequence, nucleic acid probes, and primers. The nucleic acidmolecule may be linear or circular and may contain modifications in thebackbone to increase stability and half life of such molecules inphysiological environments.

The nucleic acid may be double stranded, single stranded, or containportions of both double stranded or single stranded sequence. As will beappreciated by those in the art, the depiction of a single strand(“Watson”) also defines the sequence of the other strand (“Crick”).

By the term “recombinant nucleic acid” herein is meant nucleic acid notnormally found in nature. In general, a “recombinant nucleic acid” isoriginally constructed in vitro, e.g., by the manipulation of nucleicacid by endonucleases. Thus an isolated nucleic acid in a linear form,or an expression vector formed in vitro by ligating DNA molecules thatare not normally joined, are both considered recombinant for thepurposes of this invention. It is understood that once a recombinantnucleic acid is made and reintroduced into a host cell or organism, itwill replicate non-recombinantly, e.g., using the in vivo cellularmachinery of the host cell rather than in vitro manipulations. However,such nucleic acids, once produced recombinantly, although subsequentlyreplicated non-recombinantly, are still considered recombinant for thepurposes of the invention.

The term “endogenous”, when used in reference to a biopolymer, meansthat which is naturally produced (e.g., by an unmodified mammalian orhuman cell). As used herein, the terms “endogenous” and “native” areinterchangeable.

A “deletion” is defined as a change in the sequence of a biopolymer inwhich one or more residues are absent as compared to a sequence of aparental biopolymer. A deletion can remove about 2, about 5, about 10,up to about 20, up to about 30 or up to about 50 or more amino acids. Abiopolymer may contain more than one deletion.

An “insertion” or “addition” is a change in a sequence of a biopolymerthat results in the addition of one or more residues, as compared to asequence of a parental biopolymer. “Insertion” generally refers toaddition to one or more residues within a biopolymer, while “addition”can be an insertion or refer to amino acid residues added at an end, orboth termini, of a biopolymer. An insertion or addition is usually ofabout 1, about 3, about 5, about 10, up to about 20, up to about 30 orup to about 50 or more amino acids. A biopolymer may contain more thanone insertion or addition.

A “substitution” results from the replacement of one or more residues ofa biopolymer by different residues, as compared to a sequence of aparental biopolymer. It is understood that a polypeptide may haveconservative amino acid substitutions which have substantially no effecton activity of the polypeptide. By conservative substitutions isintended combinations such as gly, ala; val, ile, leu; asp, glu; asn,gln; ser, thr; lys, arg; and phe, tyr.

The term “assessing” includes any form of measurement, and includesdetermining if an element is present or not. The terms “determining”,“measuring”, “evaluating”, “assessing” and “assaying” are usedinterchangeably and includes quantitative and qualitativedeterminations. Assessing may be relative or absolute. “Assessing thepresence of” includes determining the amount of something present,and/or determining whether it is present or absent.

As used herein the term “isolated,” when used in the context of anisolated compound, refers to a compound of interest that is in anenvironment different from that in which the compound naturally occurs.“Isolated” is meant to include compounds that are within samples thatare substantially enriched for the compound of interest and/or in whichthe compound of interest is partially or substantially purified.

The term “isolated” also means that the recited material is usuallyunaccompanied by at least some of the material with which it is normallyassociated in its natural state, preferably constituting at least about0.5%, more preferably at least about 5% by weight of the total proteinin a given sample. “Purified” means that the recited material comprisesat least about 75% by weight of the total protein, with at least about80% being preferred, and at least about 90% being particularlypreferred.

As used herein, the term “substantially pure” refers to a compound thatis removed from its natural environment and is at least 60% free,preferably at least 75% free, and most preferably at least 90% free fromother components with which it is naturally associated.

A “coding sequence” or a sequence that “encodes” a selected polypeptide,is a nucleic acid molecule which can be transcribed (in the case of DNA)and translated (in the case of mRNA) into a polypeptide, for example, ina host cell when placed under the control of appropriate regulatorysequences (or “control elements”). The boundaries of the coding sequenceare typically determined by a start codon at the 5′ (amino) terminus anda translation stop codon at the 3′ (carboxy) terminus. A coding sequencecan include, but is not limited to, cDNA from viral, procaryotic oreucaryotic mRNA, genomic DNA sequences from viral or prokaryotic DNA,and synthetic DNA sequences. A transcription termination sequence may belocated 3′ to the coding sequence. Other “control elements” may also beassociated with a coding sequence. A DNA sequence encoding a polypeptidecan be optimized for expression in a selected cell by using the codonspreferred by the selected cell to represent the DNA copy of the desiredpolypeptide coding sequence.

“Operably linked” refers to an arrangement of elements wherein thecomponents so described are configured so as to perform their usualfunction or a function of interest. In the case of a promoter, apromoter that is operably linked to a coding sequence will effect theexpression of a coding sequence. The promoter or other control elementsneed not be contiguous with the coding sequence, so long as theyfunction to direct the expression thereof. For example, interveninguntranslated yet transcribed sequences can be present between thepromoter sequence and the coding sequence and the promoter sequence canstill be considered “operably linked” to the coding sequence. In thecontext of a D₁-X_((n))-D₂ compound of the invention, the elements ofthe compound are operably linked so as to provide for autocatalyticcyclization and production of a cyclic polymer of interest.

By “nucleic acid construct” is meant a nucleic acid sequence that hasbeen constructed to comprise one or more functional units not foundtogether in nature. Examples include circular, linear anddouble-stranded nucleic acids, extrachromosomal DNA molecules(plasmids), cosmids (plasmids containing COS sequences from lambdaphage), viral genomes comprising non-native nucleic acid sequences, andthe like.

A “vector” is capable of transferring nucleic acids into to a host cell.Typically, “vector construct,” “expression vector,” and “gene transfervector,” mean any nucleic acid construct capable of directing theexpression of a nucleic acid of interest and which can transfer nucleicacid sequences to host cells. This can be accomplished by genomicintegration of all or a portion of the vector, or transient orinheritable maintenance of the vector as an extrachromosomal element.Thus, the term includes cloning and expression vehicles, as well asintegrating vectors.

An “expression cassette” encompasses any nucleic acid for directingexpression of a coding sequence of interest. In most embodiments,express cassettes contain a coding sequence operably linked to anexpression-regulatory sequence, e.g., a promoter. Such cassettes can beconstructed in a vector in order to transfer the expression cassetteinto a host cell.

A polynucleotide is “derived from” a particular cell if thepolynucleotide was obtained from the cell. A polynucleotide may also be“derived from” a particular cell if the polynucleotide was obtained fromthe progeny of the cell, as long as the polynucleotide was present inthe original cell. As such, a single cell may be isolated and cultured,e.g., in vitro, to form a cell culture prior to isolating a nucleic acidfrom that cell.

The terms “conformationally restrained” and “conformationallyrestricted” are used interchangeable herein to describe a compound(usually a polypeptide) that contains covalent or non-covalent bondsbetween units (i.e., intramolecular bonds) (e.g., as between amino acidswithin a polypeptide) and is restricted in its conformation. Forexample, amino acids within a conformationally restrained polypeptideare generable not able to freely rotate around their peptide bonds.Conformationally restrained polypeptides, and methods for makingconformationally restrained polypeptides, are generally well known inthe art (see, e.g., U.S. Pat. No. 6,596,485).

A “cyclic polypeptide” is a type of conformationally restrainedpolypeptide that, as its name suggests, contains a cyclic polymer ofamino acids. The term “cyclic polypeptide” is used to describe apolypeptide (including a cyclic peptide) that is circularized via apeptide bond between the N and C terminal amino acids of a linearpolypeptide (as described in U.S. published patent application20040014100, for example).

Each monomer of a cyclic polypeptide may comprise an amino acid, wherean “amino acid”, as discussed above, refers to a natural amino acid(i.e., a genetically coded amino acid residue), a non-natural amino acid(for example, a non-genetically coded amino acid residue) such as ananalog of a natural amino acid or a modified amino acid (for example, anamino acid that has been conjugated to an unrelated moiety, for example,PEG). Thus, a cyclic peptide may be a polymer of monomeric units thatare: (a) natural amino acid residues; (b) non-natural amino acidresidues; or (c) both natural and non-natural amino acid residues, whichmonomeric units are covalently joined. The term “cyclic peptide”includes synthetic peptides and peptides made by a cell. Amino acids aresometimes referred to herein by standard one- or three-letter symbols(see, for example, pages 58-59, “Biochemistry” Second Ed., Voet andVoet, eds. (1995) John Wiley & Sons, Inc.). As used herein, and unlessspecifically indicated otherwise, those symbols refer to natural aminoacids as well as non-natural analogs of those non-natural amino acids.In presenting the amino acid sequence of a cyclic peptide using a linearstring of one- or three-letter symbols, it is understood that the firstand last amino acids of the string are covalently joined together. Sincesuch a molecule is circular, a cyclic peptide amino acid sequence can bewritten starting at any point of the sequence. For example, a cyclicpeptide having the amino acid sequence “SAW” is identical to a cyclicpeptide having the sequence “AWS” or “WSA”. Alternatively, cyclicpeptides can be referred to as “cyclo[X₁X₂X₃],” where X₁, X₂ and X₃ areamino acids. For example, the terms “cyclo[SAW]”, “cyclo[AWS]” and“cyclo[WSA]” refer to the same cyclic peptide. Sometimes “cyclo” will bereplaced by shorthand “c” for example, “cyclo[SAW]” may be designated“c[SAW].”

The term “test polypeptide” is a polypeptide to be tested for biologicalactivity in an assay. At the time of testing, a test polypeptide mayhave known or unknown sequence.

The term “randomized amino acid sequence” refers to a polypeptide havingan amino acid sequence that is at least partially randomized, includingfully randomized. When made recombinantly, a library of polypeptideshaving randomized amino acid sequences usually contains polypeptideshaving any of the naturally occurring amino acids, or any subsetthereof, present into at least one or all positions (e.g., at last 1, 2,3, 4, 5, about 8, about 10, about 15, about 20, usually up to at least100 or more positions) of the polypeptide. Polypeptides having arandomized amino acid sequence are usually produced using syntheticnucleic acids that contain any of the four nucleotides, or a subsetthereof, in at least one or all positions of the polynucleotide.

The term “specific binding” refers to the ability of a polypeptide topreferentially bind to a binding partner for that polypeptide that ispresent in a homogeneous mixture of different analytes. Typically, aspecific binding interaction will discriminate between binding partnersfor a polypeptide and other analytes by more than about 10 to 100-foldor more (e.g., more than about 1000- or 10,000-fold). Typically, theaffinity between a particular polypeptide and binding partner for thepolypeptide when they are specifically bound in a polypeptide/bindingpartner complex is characterized by a K_(D) (dissociation constant) ofat least 10⁻⁶ M, at least 10⁻⁷ M, at least 10⁻⁸ M, at least 10⁻⁹ M,usually up to about 10⁻¹⁰ M.

The term “polypeptide/binding partner complex” is a complex that resultsfrom the specific binding of a polypeptide to a binding partner for thepolypeptide, i.e., a “binding partner pair”. A polypeptide and a bindingpartner for the polypeptide will typically specifically bind to eachother under “conditions suitable for specific binding”, where suchconditions are those conditions (in terms of salt concentration, pH,detergent, protein concentration, temperature, etc.) which allow forbinding to occur between the members of a binding partner pair insolution. Such conditions, particularly with respect to receptors andligands, are well known in the art. Conditions suitable for specificbinding typically permit specific binding of a polypeptide to a bindingpartner with a dissociation constant (K_(D)) of less than about 10⁻⁶ Mto each other, but not to other analytes.

A “library” of cells is a plurality of cells. Such a library may be amixture of different cells, or may contain cells that are separated fromeach other (e.g., in the wells of a multi-well plate).

The terms “pool” or “mixture”, as used herein, refers to a combinationof elements, e.g., cells or polypeptides, that are interspersed in twoor three dimensions and not in any particular order. A mixture ishomogeneous and not spatially separable into its different constituents.Examples of mixtures of elements include a number of differentpolypeptides that are present in the same solution (e.g., an aqueoussolution). In other words, a mixture is not addressable. To be specific,an arrayed library of polypeptides, as is commonly known in the art, isnot a mixture of polypeptides because the elements of the library arespatially distinct and the array is addressable.

The terms “treatment”, “treating”, “treat”, and the like, refer toobtaining a desired pharmacologic and/or physiologic effect. The effectmay be prophylactic in terms of completely or partially preventing adisease or symptom thereof and/or may be therapeutic in terms of apartial or complete cure for a disease and/or adverse affectattributable to the disease. “Treatment”, as used herein, covers anytreatment of a disease in a mammal, particularly in a human, andincludes: (a) preventing the disease from occurring in a subject whichmay be predisposed to the disease but has not yet been diagnosed ashaving it; (b) inhibiting the disease, i.e., arresting its development;and (c) relieving the disease, i.e., causing regression of the diseaseand/or relieving one or more disease symptoms. “Treatment” is also meantto encompass delivery of an agent in order to provide for apharmacologic effect, even in the absence of a disease or condition. Forexample, “treatment” encompasses delivery of a receptor modulator thatcan provide for enhanced or desirable effects in the subject (e.g.,reduction of pathogen load, beneficial increase in a physiologicalparameter of the subject, reduction of disease symptoms, etc.).

“Subject”, “individual,” “host” and “patient” are used interchangeablyherein, to refer to an animal, human or non-human, susceptible to orhaving a receptor-related disorder amenable to therapy according to themethods of the invention. Generally, the subject is a mammalian subject.Exemplary subjects include, but are not necessarily limited to, humans,non-human primates, mice, rats, cattle, sheep, goats, pigs, dogs, cats,and horses, with humans being of particular interest.

Other definitions of terms appear throughout the specification.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides methods for making compositions that are usefulfor producing cyclic polymers, e.g., cyclic peptides, using a cell freesystem. In general, the method involves ligating first and secondrecombinant intein domains to a linear synthetic polymer to form acompound containing the structure: D₁-X_((n))-D₂, where D₁ is a firstcatalytic domain of an intein, D₂ is a second catalytic domain of anintein, wherein the second catalytic domain has at its N-terminus afirst reactive site for the intein, and X_((n)) is a polymer composed ofn units of monomer X, wherein the polymer has a second reactive site forthe intein at its N-terminus. A subject compound can autocatalyticallycyclize the X_((n)) polymer that is part of the compound to produce acyclic version of the polymer. Also described are libraries of suchcompounds for producing libraries of cyclic polymers. Methods of makingcyclic polymers by incubating the subject compounds are also provided.The invention finds use in a variety of drug discovery, clinical andtherapeutic applications.

In further describing the invention in greater detail than provided inthe Summary and as informed by the Background and Definitions providedabove, the subject compositions and methods for making cyclic polymerswill be described first, followed by a discussion of the compositionsproduced by the subject methods. This discussion is followed by a reviewof representative applications in which the subject methods andcompositions find use.

Compositions and Methods for Making Cyclic Polymers

As mentioned above, the invention provides an in vitro, i.e., cell-free,method for cyclizing a linear polymer. In general terms, the methodinvolves two steps: an in vitro ligation step and an in vitro inteinreaction step. The general features of the method are schematicallyillustrated in FIG. 1. Typically, and with reference to FIG. 1, twodomains of an intein (i.e., first and second catalytic intein domains D1and D2) are ligated to a synthetic polymer of monomer sequence X_((n)),to produce a recombinant intein composition of the formulaD1−X_((n))-D2, where “—” is a covalent bond, typically a peptide bond.This recombinant composition, when subjected to suitable in vitro inteinreaction conditions, autocatalyzes cyclization of the linear polymer toproduce a cyclic polymer comprising the sequence X_((n)). Accordingly,the invention may be used to produce a cyclic polymer having a monomersequence X_((n)) from a linear polymer containing the same sequence asthe cyclic polymer.

From this point forward, an intein/polymer composition having theformula D1-X_((n))-D2, as described above, will be referred to as an“intein composition”.

In further describing these methods, the subject inteins and polymerswill be described first, followed by a review of methods by which theymay be ligated together to produce a linear intein composition. Methodsfor producing cyclic polymers using an intein composition are thendescribed.

Inteins

The inteins that may be used in the subject methods are capable ofprotein splicing in trans or cis. Such inteins are well known in the artand are reviewed in a number of publications, including Paulus (AnnualReview of Biochemistry, 2000, 69: 447-496), Paulus (Chemical SocietyReviews 1998 27:375-386), Paulus (Bioorganic Chemistry 2001 29:119-129)and published U.S. patent applications 20040014100 and 20030013148. Acomprehensive list of inteins and description of their biology may befound at New England Biolabs Intein Database (InBase Reference: Perler,F. B. (2002). InBase, the Intein Database. Nucleic Acids Res. 30,383-384), as found at the world wide website of New England Biolabs.

Inteins of any origin (i.e., naturally occurring inteins orcatalytically active naturally occurring or man-made variants thereof)may be employed in the methods described herein. An intein may be ofbacterial, yeast, mammalian or viral origin, for example. Accordinglyand without wishing to limit the invention to any particular intein,exemplary inteins for use in the subject methods include: the Ssp DnaBintein from Synechocystis spp. strain PCC6803, the Mxe GyrA intein fromMycobacterium xenopi, the CIV RIR1 intein from Chilo iridescent virus,the Ctr VMA intein from Candida tropicalis, the Gth DnaB intein fromGuillardia theta, the Ppu DnaB intein from Porphyra purpurea, the SceVMA intein from Saccharomyces cerevisiae, the Mf1 RecA intein fromMycobacterium flavescens, the Ssp DnaE intein from Synechocystis spp.strain PCC6803, the Mle DnaB intein from Mycobacterium leprae, the MjaKIbA intein from Methanococcus jannaschii, the Pfu KIbA from Pyrococcusfuriosus, the Mth RIR1 intein from Methanobacterium thermoautotrophicum(delta H strain), the Pfu RIR1-1 intein from Pyrococcus furiosus, thePsp-GBD Pol intein from Pyrococcus spp. the GB-D, Thy Pol-2 intein fromThermococcus hydrothermalis, the Pfu IF2 intein from Pyrococcusfuriosus, Pho Lon intein from Pyrococcus horikoshii OT3, the Mja r-Gyrintein from Methanococcus jannaschii, the Pho RFC intein from Pyrococcushorikoshii OT3, the Pab RFC-2 intein from Pyrococcus abyssi, the MjaRtcB (Mja Hyp-2) intein from Methanococcus jannaschii, the Pho VMAintein from Pyrococcus horikoshii OT3, the Mtu RecA intein, the PI-pfuIintein and the PU-pfu II intein, and artificial trans-splicing variantsthereof.

As is well recognized in the art, inteins typically are composed of twodomains (termed herein the “N-terminal domain” and “C-terminal domain”)that can be naturally (in the case of the Ssp DnaE intein, for example)or non-naturally (i.e., artificially or by recombinant means, forexample) present as two different molecules. These intein domains, whenpresent together, can reconstitute an active intein, and can be used tojoin two different polypeptides together in trans or in cis. Also aswell recognized in the art, inteins may be used to produce cyclicpeptides in vivo and in vitro. Such methods are generally described inpublished U.S. patent application 20040014100, Camarero and Muir (J. Am.Chem. Soc. 1999 121:5597-5598), Iwai and Pluckthun (FEBS Lett. 1999459:166-172), Evans, et al. (J. Biol. Chem. 1999 274:18359-18363) andScott et al. (Proc. Natl. Acad. Sci. 1999 96:13638-13643). Any inteinmay be used to make a cyclic peptide.

As mentioned above, the N- and C-terminal domains of an intein may beused to effect splicing in cis or in trans. Since those domains will beused in the methods described herein in cis (i.e., as part of the samemolecule), but in a different order in which they may naturally occur,the C- and N-terminal intein domains, as used in an intein compositiondescribed in great detail below, will be referred to herein as first andsecond intein catalytic domains, respectively. In other words, as iswell known in the art, an intein typically consists of two inteindomains, i.e., an N-terminal domain and a C-terminal domain, thattogether can auto-catalyze an intein-mediated splicing reaction in cisor in trans. Since the intein compositions described herein typicallycontain an N-terminal intein domain at the C-terminal end of thecomposition, and a C-terminal intein domain at the N-terminal end of thecomposition, the C- and N-terminal domains of an intein are hereintermed first and second catalytic intein domains, respectively. Inparticular embodiments, the first and second catalytic intein domainsmay be referred to as “D1” (or “D₁”) and “D2” (or “D₂”), respectively.Accordingly, the first and second catalytic intein domains referred toherein correspond to the C- and N-terminal domains of a so called“split” intein (i.e., an naturally or artificially split intein) which,together, can effect a protein splicing reaction. The relationshipbetween the described N- and C-terminal intein domains and the first andsecond catalytic intein domains used in the instant methods is describedin FIG. 2.

Naturally-occurring intein-mediated protein splicing proceeds accordingto one of two pathways, a classical and alternative pathway depending onwhich particular intein is used. Naturally-occurring inteins thatcatalyze splicing using the classical pathway, such as many of thoselisted above, typically contain a N-terminal cys or ser amino acid as anintein reactive site. Naturally-occurring inteins that catalyze splicingusing the alternative pathway, such as the M. jannaschii KlbA intein,and others, typically use a N-terminal ala amino acid as an inteinreactive site. Almost all naturally-occurring inteins contain a ser, cysor thr amino acid as a C-terminal intein reactive site. Accordingly, inperforming the subject methods, a wide variety of amino acids may bechosen for use at intein-reactive sites.

Since the N-terminal amino acid of an N-terminal domain of an intein maycontains an intein reactive amino acid containing a hydroxyl (OH) orthiol (SH) group (e.g., a cys or ser or analog thereof), or ala oranalog thereof, so too does the N-terminal amino acid of the secondintein domain (D₂) typically used in the subject methods. Furthermore,since the C-terminal domain of an intein typically, but not always, endsits C-terminus in the his-asn dimer, so, too, do many of the firstcatalytic intein domains (D₁) used in the subject methods. As would berecognized by one of skill in the art, there is considerable flexibilityat the “his-asn” position, and, accordingly other amino acid dimers,e.g., gly-asn, gly-gln, ser-asn, ala-asn, phe-asn, lys-asn, etc., oranalogs thereof, may be present at this position instead of his-asn. Therelationship between the described intein domains, the first and secondcatalytic intein domains used in the instant methods, and the variousgroups and dimer motifs discussed above, is described in FIG. 2.

An intein domain used in the present invention may be produced and/orused as a fusion protein, particularly as a fusion protein containing anaffinity tag that can aid in purification of the protein and/orseparation of the protein from other compounds (e.g., cyclic peptideproducts). Suitable affinity tags include any amino acid sequence thatmay be specifically bound to another moiety, usually anotherpolypeptide, most usually an antibody. Suitable affinity tags includeepitope tags, for example, the V5 tag, the FLAG tag, the HA tag (fromhemagglutinin influenza virus), the myc tag, and the like, as is knownin the art. Suitable affinity tags also include domains for which,binding substrates are known, e.g., HIS, GST and MBP tags, as is knownin the art, and domains from other proteins for which specific bindingpartners, e.g., antibodies, particularly monoclonal antibodies, areavailable. Suitable affinity tags also include any protein-proteininteraction domain, such as a IgG Fc region, which may be specificallybound and detected using a suitable binding partner, e.g. the IgG Fcreceptor.

Prior to their ligation to a polymer, the subject first and secondcatalytic intein domains are typically produced using recombinant means,and purified. Methods for producing and isolating polypeptides are wellknown in the art (Ausubel, et al, Short Protocols in Molecular Biology,5th ed., Wiley & Sons, 2002; Sambrook, et al., Molecular Cloning: ALaboratory Manual, Third Edition, (2001) Cold Spring Harbor, N.Y.) andneed not be discussed in any more detail than that set forth above. Incertain embodiments, an intein domain may be produced by cleavage of alarger protein, e.g., a mutant or wild type intein, with a cleavageagent, e.g., a thiol-containing agent or the like, for example, MESN,thiophenol or the like, to produce the intein domain. In particularembodiments, a variant form of an intein that is defective in completionof the splicing reaction but still capable of thioester intermediateformation may be cleaved to generate a first or second catalytic inteindomain. Such inteins may be used to produce a intein domain containing areactive thioester group, and are well known in the art (e.g., Xu et al.EMBO J. 1996 15: 5146-5153; Chong et al. Gene 1997 192:271-281). Such anintein, and a cleavage reaction producing a first catalytic inteindomain, is exemplified in FIG. 3A.

Polymers of Interest

Any type of polymer may be cyclized using the subject methods, includingorganic polymers such as biopolymers that contain amino acid ornucleotide monomers, or a mixture of different types of monomers.Accordingly, polypeptides, polynucleotides, or a polymer containing bothamino acid and nucleotide monomers, for example, may be cyclized usingthe subject methods. In many embodiments of the invention, the polymerused is a biopolymer containing amino acids, i.e., a polypeptide.Polymers that may be employed in the subject methods may not contain anypeptide bonds. However, in certain embodiments, the polymers may containpeptide bonds in between the first and second monomers of one or bothends of the polymer to be cyclized. In certain embodiments, the subjectpolymers may contain thioester bonds, for example, between the first andsecond monomers of one or both ends of the polymer to be cyclized.

A polymer for use as a component X_((n)) of subject D₁-X_((n))-D₂compounds may be made in a cell, e.g., by recombinant means, orsynthetically (i.e., using a cell-free system, e.g., by employing amachine or in solution). Biopolymers used in the subject methods aregenerally synthetic biopolymers, and may be non-naturally occurring, maycontain non-naturally occurring monomers, may contain a mixture ofnaturally occurring and non-naturally occurring monomers, and may not begenetically encodable, i.e., cannot be made in a cell. In certainembodiments, a synthetic biopolymer may contain only naturally occurringmonomers, and, as such, may be identical to a naturally-occurring formor naturally produced form of the biopolymer. Methods for makingsynthetic biopolymers, e.g., synthetic polypeptides, are well known inthe art and do not need to be described here in any great detail.

For example, biopolymers, e.g., polypeptides, can be produced bychemical synthesis, for example, by the solid phase peptide synthesismethod of Merrifield et al. (J. Am. Chem. Soc. 1964 85:2149). Standardsolution methods may also be used (see, for example, Bodanszky,Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) andBodanszky, Peptide Chemistry, Springer-Verlag, Berlin (1993)). Subjectbiopolymers can be chemically synthesized by the methods of Creighton(1983, Proteins: Structures and Molecular Principles, W.H. Freeman &Co., N.Y.) or Hunkapiller et al. (Nature, 310:105-111 (1984)).

Biopolymers may be produced using a biopolymer synthesizer (e.g. apeptide synthesizer of Applied Biosystems, Foster City, Calif.).Furthermore, if desired, non-naturally amino acids or chemical aminoacid analogs can be introduced into a polypeptide sequence.Non-classical amino acids include non-genetically encodable amino acids(i.e., amino acids that cannot be produced and used to make protein in acell using ribosomes), such as the D-isomers of the common amino acids,2,4-diaminobutyric acid, α-amino isobutyric acid, 4-aminobutyric acid,Abu, 2-amino butyric acid, γ-Abu, ε-Ahx, 6-amino hexanoic acid, Aib,2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine,norvaline, 5 hydroxyproline, sarcosine, citrulline, homocitrulline,cysteic acid, t-butylglycine, t-butylalanine, phenylglycine,cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acidssuch as b-methyl amino acids, Ca-methyl amino acids, Na-methyl aminoacids, and amino acid analogs in general. Furthermore, the amino acidscan be D (dextrorotary) or L (levorotary). Further methods and aminoacid analogs for peptide synthesis may be found in Chan et al, (Fmocsolid phase peptide synthesis: A Practical Approach, Oxford UniversityPress, 2000) and Bodanszky (Principles of Peptide Synthesis, SpringerVerlag, 2nd edition, 1993).

A newly synthesized biopolymer may be further chemically modified, e.g.,glycosylated, acetylated, PEGylated, etc. before use. Subjectbiopolymers can be purified, for example, by high performance liquidchromatography (HPLC), and can be characterized using, for example, massspectrometry or sequence analysis, prior to use in the subject methods.

A polymer of interest may be at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or12 monomers, or more than 12 monomers in length, usually up to about 20,30, 40, 50 or 100 or 1000 or more monomers in length. Accordingly, apeptide employed in the subject methods may contain at least 2, 3, 4, 5,6, 7, 8, 9, 10, 11 or 12 amino acids, or more than 12 amino acids,usually up to about 20, 30, 40 or 50 amino acids (e.g., non-naturallyoccurring amino acids, naturally occurring amino acids or a mixturethereof). Polymers of particular interest are 2-50, 3-40, 4-30, 3-8,5-20 or 6-10 monomers in length, and typically range from 500-5000 Da,600-4000 Da, 700-2000 Da in molecular weight. The subject polymers maybe described using the formula X_((n)), where X is any monomer, and n isthe number of those monomers in the polymer, e.g., as exemplified above.X₁ is the first monomer in a subject polymer, and X_(n), is the lastmonomer in the polymer.

The monomer at one end of the subject polymer, typically the N-terminalend of the polymer is a polypeptide, is usually an intein-reactive aminoacid, i.e., an amino acid that can be joined to another amino acid by anintein. The intein-reactive amino acid of the polymer contains ahydroxyl (OH) or thiol (SH) group (e.g., a cys, ser or thr amino acid oranalog thereof, etc.). An exemplary subject polymer having sequenceX_((n)) is shown in FIG. 2. Solely for ease of description, the inteinreactive site present in the polymer is termed the first intein-reactivesite and the intein reactive site present in the second intein domain istermed the second intein-reactive site.

In particular embodiments, and depending on the exact ligation methodsused, the monomer at the other end of the polymer (i.e., the C-terminalend if the polymer is a polypeptide) may also be an amino acid. In otherembodiments, the monomer at the other end of the polymer (i.e., theC-terminal end if the polymer is a polypeptide) may contain anactivatable or activated reactive group (e.g. a group that is activatedwhen the polymer is cleaved from a solid support, for example aresin-activated thioester group), that facilitates ligation of that endof the polypeptide to the second intein domain.

In certain embodiments, a polymer may be a polypeptide containingnon-natural amino acids which generally contain any combination ofnon-natural components, including: a) residue linkages other thannatural amide bonds (“peptide bonds”); and/or b) non-natural amino acidresidues in place of natural amino acid residues.

Linkages other than natural amide bonds (i.e., —C(═O)NH—) that may beemployed in the subject compositions include, but are not limited to:ketomethylene bonds (for example, —C(═O)—CH₂—), aminomethylene bonds(CH₂—NH), ethylene bonds (—C₂H₄—), olefin bonds (—CH═CH—), ether bonds(—CH₂—O—), thioether bonds (—CH₂—S—), tetrazole bonds (CN₄—), as well asthiazole, retroamide, thioamide, and ester bonds. Such “surrogate”peptide bonds are well known in the art (see, for example, Spatola(1983) in Chemistry and Biochemistry of Amino Acids, Peptides andProteins, Vol. 7, pp 267-357, A Peptide Backbone Modifications, MarcellDekker, NY) and are readily employed herein. For ease of description,such linkages may still termed “peptide” or “amino” bonds herein,although the linkage may not have a conventional “peptide” or “amino”bonds structure: —C(═O)NH—

Further, as mentioned above, a polymer may contain natural ornon-natural amino acids, where natural and non-natural amino acids areclassified according to Table 1.

The non-natural amino acids of Table 1 are abbreviated as follows: aminoβ-alanine (β-Ala) and other omega-amino acids such as 3-aminopropionicacid (Dap), 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and soforth; α-aminoisobutyric acid (Aib); ε-aminohexanoic acid (Aha);δ-aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly);ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA);t-butylglycine (t-BuG); N-methylisoleucine (MeIle); phenylglycine (Phg);cyclohexylalanine (Cha); norleucine (Nle); 2-naphthylalanine (2-Nal);4-chlorophenylalanine (Phe(4-Cl)); 2-fluorophenylalanine (Phe(2-F));3-fluorophenylalanine (Phe(3-F)); 4-fluorophenylalanine (Phe(4-F));penicillamine (Pen); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid(Tic); 13-2-thienylalanine (Thi); methionine sulfoxide (MSO);homoarginine (hArg); N-acetyl lysine (AcLys); 2,3-diaminobutyric acid(Dab); 2,4-diaminobutyric acid (Dbu); p-aminophenylalanine (Phe(pNH₂));N-methyl valine (MeVal); homocysteine (hCys) and homoserine (hSer).

TABLE 1 Classification Natural Non-natural Aromatic F, Y, W Phg, Nal,Thi, Tic, Phe(4-Cl), Phe(2-F), Phe(3-F), Phe(4-F), Pyridyl Ala,Benzothienyl Ala Apolar L, V, I, A, M T-BuA, T-BuG, MeIRe, Nle, MeVal,G, P Cha, MeGly, Aib Aliphatic A, V, L, I t-BuA, t-BuG, MeIle, Nle,MeVal, Cha, bAla, MeGly, Aib, Dpr, Aha Acidic D, E phenyl alaninepara-carboxylic acid Basic H, K, R Dpr, Orn, hArg, Phe(p-NH₂), Dbu, DabPolar Q, N, S, T, Y Cit, AcLys, MSO, hSer, bAla Cysteine-Like C Pen,hCys, p-methyl Cys

Each class of amino acids set forth in Table 1 is discussed in greaterdetail below:

A hydrophobic amino acid is an amino acid exhibiting a hydrophobicity ofgreater than zero according to the normalized consensus hydrophobicityscale of Eisenberg et al. (1984, J. Mol. Biol. 179: 125-142). Examplesof natural hydrophobic amino acids include Pro, Phe, Trp, Met, Ala, Gly,Tyr, Ile, Leu and Val. Examples of non-natural hydrophobic amino acidsinclude t-BuA.

An aromatic amino acid is a hydrophobic amino acid having a side chaincontaining at least one aromatic or heteroaromatic ring. The aromatic orheteroaromatic ring may contain one or more substituents such as —OH,—SH, —CN, —F, —Cl, —Br, —I, —NO₂, —NO, —NH₂, —NHR, —NRR, —C(O)R,—C(O)OH, —C(O)OR, —C(O)NH₂, —C(O)NHR, —C(O)NRR and the like where each Ris independently optionally substituted C₁-C₆ alkyl, optionallysubstituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl,optionally substituted C₆-C₂₀ aryl C₀-C₆ alkyl and optionallysubstituted C₅-C₁₅ heteroaryl C₀-C₆ alkyl. Examples of natural aromaticamino acids include Phe, Tyr and Trp. Commonly encountered non-naturalencoded aromatic amino acids include phenylglycine, 2-naphthylalanine,β-2-thienylalanine, 1,2,3,4-tetrahydroisoquinolin-e-3-carboxylic acid,4-chloro-phenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine and4-fluorophenylalanine. Aromatic rings of a non-natural amino acidinclude, thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl,furanyl, pyrrolyl, and pyridyl aromatic rings.

An “apolar” or “non-polar” amino acid is a hydrophobic amino acid havinga side chain that is uncharged at physiological pH and which has bondsin which the pair of electrons shared in common by two atoms isgenerally held equally by each of the two atoms (i.e., the side chain isnot polar). Examples of natural apolar amino acids include Gly, Leu,Val, Ile, Ala and Met. Examples of non-natural apolar amino acidsinclude Cha.

An aliphatic amino acid is a hydrophobic amino acid having an aliphatichydrocarbon side chain. Examples of natural aliphatic amino acidsinclude Ala, Leu, Val and Ile. Examples of non-natural aliphatic aminoacids include Nle.

A hydrophilic amino acid is an amino acid exhibiting a hydrophilicity ofless than zero according to the normalized consensus hydrophobicityscale of Eisenberg et al. (1984, J. Mol. Biol. 179: 125-142). Examplesof natural hydrophilic amino acids include Thr, His, Glu, Asn, Gln, Asp,Arg, Ser and Lys. Examples of natural hydrophilic amino acids includeCet and hCys.

An acidic amino acid is a hydrophilic amino acid having a side chain pKvalue of less than 7. Acidic amino acids typically have negativelycharged side chains at physiological pH due to loss of a hydrogen ion.Examples of natural acidic amino acids include Asp and Glu.

A basic amino acid is a hydrophilic amino acid having a side chain pKvalue of greater than 7. Basic amino acids typically have positivelycharged side chains at physiological pH due to association withhydronium ion. Examples of natural basic amino acids include Arg, Lysand His. Examples of non-natural basic amino acids include thenon-cyclic amino acids ornithine, 2,3-diaminopropionic acid,2,4-diaminobutyric acid and homoarginine.

A polar amino acid is a hydrophilic amino acid having a side chain thatis uncharged at physiological pH, but which has one bond in which thepair of electrons shared in common by two atoms is held more closely byone of the atoms. Examples of natural polar amino acids include Ser,Thr, Asn and Gln. Examples of non-natural polar amino acids includecitrulline, N-acetyl lysine and methionine sulfoxide.

The amino acid residue Cys has the ability to form disulfide bridgeswith other Cys residues or other sulfanyl-containing amino acids. Cys isclassified as a polar hydrophilic amino acid for the purposes of thepresent invention. Typically, cysteine-like amino acids generally have aside chain containing at least one thiol (SH) group. Examples ofgenetically encoded cysteine-like amino acids include Cys. Examples ofnon-genetically encoded cysteine-like amino acids include homocysteineand penicillamine.

Further non-natural amino acids are described in U.S. patent applicationSer. No. 10/197,927, published as US20030166138, which publication isincorporated herein for all purposes.

Exemplary 3-monomer and 4-monomer-containing cyclic polymers that may bemade using the methods described herein may be found U.S. provisionalpatent applications each entitled “INHIBITORS OF IRES-MEDIATEDTRANSLATION AND METHODS OF USE” 60/677,159, 60/677,041 and 60/677,030),filed on May 2, 2005.

Ligation Methods

As discussed above, a first intein domain, a second intein domain, and asubject polymer are ligated together to form an intein compositionhaving the formula D1-X_((n))-D2, where “—” is a covalent bond,typically a peptide bond. A wide variety of methods are available forligating polypeptides to polymers via peptide bonds, particularlypolymers that contain amino acids both of their ends. Accordingly, asubject intein composition may be made a number of ways.

Typically, the subject intein compositions are made using a “step-wise”approach, however, because different methods may ligate only certainamino acids and not others, and because amino acids may be specificallychosen because they can be ligated to each other and not to others(e.g., through a chemoselective reaction), certain embodiments of thesubject ligation methods do not require that the components are ligatedusing a step-wise approach, e.g., the components are simultaneouslyligated in a single reaction vessel. If a step-wise approach is used,the first or the second intein domain is first ligated to the polymer toform an intermediate product, and the remaining intein domain is ligatedto the intermediate product to form a subject intein composition. Ifsuch step-wise methods are used, one end of the polymer may beprotected, as discussed above, until the intermediate product hasformed. Upon production of the intermediate product, the polymer may bede-protected, allowing that end of the polymer to react with theremaining intein domain to form a subject intein composition.

Methods for ligating polypeptides to amino acid-containing syntheticpolymers via peptide bonds are well known in the art and are describedin Dawson and Kent (Synthesis of Native Proteins by Chemical Ligation,Annu. Rev. Biochem. 2000, 69:923-60). In particular embodiments, thepolypeptide and polymer are linked using a process called “nativechemical ligation” in which an N-terminal sulfhydryl- (i.e., thiol-)containing peptide is chemically ligated to a peptide having aC-terminal thioester group, with the resultant formation of a peptidebond at the ligation site (see e.g., U.S. Pat. No. 6,184,344 and Dawsonet al. (Science. 1994 266:776-9)). Such methods may be used to ligateany amino acid at the C-terminus of a peptide to an N-terminalsulfhydryl group of a second peptide (e.g., a cysteine residue of thesecond peptide, or any other sulfhydryl-containing amino acid). SeeHackeng et al. (Proc. Natl. Acad. Sci. 1999 96: 10068-10073) for adescription of these native chemical ligation methods. In addition tosulfhydryl-containing amino acids, native chemical ligation methods havealso be used to ligate peptides that have a C- or N-terminal naturallyoccurring glycine, and other amino acid (see U.S. Pat. No. 6,307,018).Further methods for ligating an intein to a polymer are described inMuir et al. (Proc. Natl. Acad. Sci. 1998 95:6705-6710) and publishedU.S. published patent application 20020151006. Muir et al and20020151006 generally provide methods in which a precursor polypeptideis cleaved using a thiol cofactor, e.g., thiophenol, MESNA, or the like,to produce a polypeptide with a reactive thioester group that can beligated to any peptide having an N-terminal unprotected sulphydrylgroup. Finally, Evans et al. (U.S. published patent application20030013148) discuss an intein-related method in which polypeptides canbe ligated together on a solid support.

Other ligation methods suitable for use in the subject methods aredescribed in Schlolzer et al. (Science 1992 256:221-225), Rose et al.(Am. Chem. Soc. 1994 116:30-34); Liu et al. (Proc. Natl. Acad. Sci, 199491:6584-6588), Canne et al. (J. Am. Chem. Soc. 1995 117:2998-3007) andBaca et al. (J. Am. Chem. Soc. 1995 117: 1881-1887).

According, the instant methods generally involve ligating first andsecond recombinant intein domains to a synthetic polymer to form acompound containing the structure D₁-X_((n))-D₂, where D₁ is a firstcatalytic domain of an intein; X_((n)) is a polymer containing nresidues of a monomer X, where n is at least 2, and wherein the polymerhas a first reactive site for the intein at one end (typically itsN-terminus if the polymer is a peptide); and where D₂ is a secondcatalytic domain of an intein, said second catalytic domain having atits N-terminus a second reactive site for the intein.

In many embodiments, the ligation methods involve ligating a firstcatalytic domain of an intein with a synthetic polymer to produce acompound of the formula D₁-X_((n)), where D₁ and X_((n)) are joined by afirst peptide bond, and ligating said second catalytic domain of anintein with said synthetic polymer to produce a compound of the formulaD₁-X_((n))-D₂ where D₁ and X_((n)) are joined by a second peptide bond.

In certain embodiments, the subject ligation methods involve ligating afirst catalytic domain of an intein having a C-terminal reactivethioester with a synthetic polymer, said synthetic polymer having asulfhydryl group at one terminus and a protected thioester group at theother terminus to produce a compound of the formula: D₁-X_((n))—Z, whereD₁ is said first catalytic domain of an intein, X_((n)) is a polymercontaining n residues of a monomer X, where n is at least 2, and Z is aprotected thioester group, deprotecting the protected terminal thioestergroup to produce a terminal reactive thioester group; and ligating theterminal reactive thioester group with said second catalytic domain ofan intein having an N-terminal sulfhydryl group to produce a compound ofthe formula: D₁-X_((n))-D₂.

As discussed above, the first and second reactive sites may containsulfhydryl or hydroxyl groups (e.g., cys, ser, thr), or, in certainembodiments, may be an ala or analog thereof.

Accordingly, a first intein domain, a second intein domain, and asubject polymer are ligated together to form an intein compositionhaving the formula D1*X_((n))*D2, where “*” is a peptide bond. The abovediscussion describes a method in which the first intein-reactive site isdonated to the intein composition via the first monomer of the polymerand the second reactive site is donated to the intein composition viathe first amino acid of the second intein domain. It is recognized thatthe same intein composition can be made by donating the firstintein-reactive site via the C-terminus of the first intein domainand/or by donating the second intein-reactive site via the N-terminus ofthe polymer. Accordingly, when an intein composition having thestructure D₁-X_((n))-D₂, D₂ having a first reactive site at itsN-terminus (i.e., the end closest to the N-terminus of the inteincomposition) a first intein reactive site and X_((n)) having a secondreactive site for said intein at its N-terminus, or grammaticalequivalents thereof, is recited, intein compositions made by these othermethods are encompassed.

Intein Reaction Conditions

Once made, an intein composition is typically maintained in inteinreaction conditions to produce a cyclic peptide via an autocatalyticprocess (see FIG. 2). Intein reaction conditions may vary depending onthe intein used and if such conditions are not already known, they canbe readily determined without undue effort. In vitro intein reactionconditions for many inteins are known (Yamazaki, et al., J. Am. Chem.Soc. 120:5591-5592 (1998), Wu, et al., Biochim. Biophys Acta,1387:422-432 (1998), Mills, et al., Proc. Natl. Acad. Sci. USA,95(7):3543-3548 (1998), Otomo, et al., J. Biomol. NMR, 14(2):105-114,Otomo, et al. Biochemistry, 39(49):16040-16044, and Southworth, et al.,EMBO J., 17(4):918-926 (1998)), and may be readily used in the instantmethods. In particular embodiments, salt concentration, pH, ortemperature of the intein composition may be adjusted to provide inteinreaction conditions. In other embodiments, a molecule, e.g., a reducingagent or denaturant, may added to provide intein reaction conditions.

For example, the Ssp DnaE split intein is less active at 37° C. than at15° C., and is less active at pH>10 than at a neutral pH. Similarly, theSsp DnaB intein used in the example set forth below is active at 25° C.at pH 7.0, and inactive at 4° C. Prior to the cyclization reaction, theintein composition is typically maintained in conditions that are notintein reaction conditions, e.g., 4° C.

If desired, cyclic polymers produced by the above methods may beseparated from the intein bioproducts using any suitable means,including size exclusion chromatography, filtration or by affinitychromatography, e.g., employing affinity tags that are part of theintein domains used.

Compositions Produced by the Subject Methods

Intein Compositions

The invention provides an intein composition having the structure:D₁-X_((n))-D₂, where D₁ is a first catalytic domain of an intein; D₂ isa second catalytic domain of an intein having at its N-terminus a firstreactive site for said intein, and where X_((n)) is a polymer having nresidues of a monomer X, wherein n is at least 2, and where the polymerhas a second reactive site for said intein at its N-terminus. In certainembodiments, the first and second ends of a polymer that is part of anintein composition are designated as the “N-terminus” and “C-terminus”of the polymer. These designations are solely intended to indicate theorientation of the polymer in an intein composition and are not meant toimply that the polymer is a polypeptide, or that it contains any aminoacids. In other words, the end of a polymer that is joined to theC-terminal end of D₁ is designated as the N-terminus of the polymer, andthe end of the polymer that is joined to the N-terminal end of D₂ isdesignated as the C-terminus of the polymer. Accordingly, while apolymer may contain no amino acids and may not be a polypeptide, it maystill contain an N-terminal end and a C-terminal end. As shown in FIG.2, intein compositions contain an N-terminus and a C-terminus by virtueof the fact that the intein compositions contain proteinaceous inteindomains. The N-terminus of the polymer portion of an intein compositionis the end of the polymer that is closest to the N-terminus of inteincomposition. Similarly, the C-terminus of a polymer portion of an inteincomposition is the end of the polymer that is closest to the C-terminusof the intein composition. As discussed above, D₁, X_((n)) and D₂ aretypically joined by covalent, e.g., peptide, bonds. In certainembodiments, therefore, the intein compositions described herein are ofthe formula D1*X_((n))*D2, where “*” is a peptide bond.

An intein composition produced by the subject methods is a catalyticallyactive intein that is capable of autocatalytically cyclizing the polymerwhich is part the intein composition under intein reaction conditions.Such intein compositions therefore typically have two intein reactivesites, one positioned at the N-terminus of the polymer and the otherpositioned at the N-terminus of the C-terminal intein domain (see FIG.2). As discussed above, intein reactive sites typically, although notalways, are amino acids containing an OH or SH group (e.g., cys, ser oranalogs thereof) or an ala or analog thereof, and in certainembodiments, the C-terminal amino acid of the N-terminal intein domainmay contain an his-asn/gln motif, although other motifs are readilyused. FIG. 2 shows an intein composition having many of the featuresdescribed above.

Since a subject intein composition may contain a synthetic biopolymer,e.g., containing analogs of naturally occurring monomers, e.g., aminoacids, it may be referred to as a “semi-synthetic” composition in whicha first part of the composition (i.e., the C- and N-terminal inteindomains) are made in a cell, and a second part of the composition (i.e.,the polymer) is made synthetically. As discussed above, the polymerregion of an intein composition may contain one or many non-naturallyoccurring amino acids and in certain embodiments, may contain onlynon-naturally occurring amino acids.

In certain embodiments, a subject intein composition may be part of alibrary of intein compositions containing polymers of different chemicalstructure. Such libraries are typically used to produce libraries ofcyclic polymers for use in drug screening assays. For example, subjectpolymers, e.g., polypeptides, may contain a randomized sequence ofmonomers, e.g., nucleotides and/or amino acids. Since a wide variety ofchemistries are available for the synthetic production of polymers,intein compositions containing an almost limitless number of differentpolymers could be made. Typically, the subject intein compositionlibraries contain a plurality (i.e., at least 5, 10, 20, 50, 100, 200,500, 1000, 2000, 5000, 10,000, 50,000, 100,000, usually up to about500,000 or 1,000,000 or more) of different intein compositions (i.e.,intein compositions containing polymer regions of different chemicalstructure, e.g., different sequences of monomers).

In certain embodiments, a subject intein composition library contains amixture of different intein compositions. In other embodiments, however,a subject intein composition library does not contain a mixture ofintein compositions. In such embodiments, each member of an subjectlibrary may be separately aliquoted in a suitable container, e.g., atube or well of a multi-well plate.

As will be discussed in greater detail below, the product cyclicpeptides contain an amino acid “Y” that is produced by the reactionbetween the two intein reactive sites of the intein composition.Accordingly, in some embodiments, the subject intein composition may bedescribed by the formula D₁-Y—X_(n)-D₂ or D₁-X_(n)—Y-D₂, where Y is anamino acid containing a OH or SH group, e.g., a cys, ser or thr, oranalog thereof.

Cyclic polymers produced using the above-described methods may contain abiopolymer of interest, as described above, plus at least one amino acidthat is produced as a product of an intein-mediated reaction between thefirst and second reactive sites in an intein composition. This aminoacid may be ser, cys or thr. However, since a wide range of chemistriesare available, other amino acids, including naturally occurring andnon-naturally occurring amino acids containing an SH or OH group, forexample, may be present. An exemplary cyclic polymer is shown at thebottom of FIG. 2, wherein “Y” is an intein reaction product amino acidas discussed above. Accordingly, all positions of a subject cyclicpolymer except for one position—that of “Y”—may be variable, and aredetermined by the sequence of the polymer used. One position of asubject cyclic polymer is typically non-variable, and is determined bythe chemistry of the intein reactive sites used.

Accordingly, cyclic peptides produced by the subject methods typicallycomprise the structure:

where Y is an amino acid incorporated as a result of the intein-mediatedreaction between the first and second reactive sites in an inteincomposition, and X_((n)) is a polymer, as discussed above. Y can be ser,cys or thr or another amino acid, for example.

In particular embodiments, a cyclic polymer produced by the instantmethods may contain 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more monomers, andmay further include the “Y” amino acid discussed in the previousparagraph.

In certain embodiments, a subject cyclic polymer may be part of alibrary of cyclic polymers, each member of the library having adifferent chemical structure. For example, the subject cyclic polymers,may contain a randomized sequence of monomers, e.g., nucleotides and/oramino acids. Since a wide variety of chemistries are available for thesynthetic production of polymers, the subject cyclic polymers librariesmay contain an almost infinite number of chemical structures. Typically,a subject cyclic polymer libraries contains a plurality (i.e., at least5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10,000, 50,000, 100,000,usually up to about 500,000 or 1,000,000 or more) of different cyclicpolymers (e.g., cyclic biopolymers having different chemical structures,for example, different sequences of monomers).

In certain embodiments, a subject cyclic peptide library contains amixture of different cyclic peptides. In other embodiments, however, asubject cyclic polymer library does not contain a mixture of cyclicpolymers. In such embodiments, each member of an subject library may beseparately aliquoted in a suitable container, e.g., a tube or well of amulti-well plate.

Utility

The subject methods and compositions may be used to make a cyclicpolymer. The subject methods and compositions find particular use inproducing cyclic polymers, particularly biopolymers that are notgenetically encodable. The subject methods may also be used forproducing libraries of cyclic polymers, particularly libraries of cyclicpeptides, for use in screening assays to identify biologically activecyclic polymers. In certain embodiments, such a biologically activecyclic polymer may be used as a drug to treat a disease or condition,e.g., cancer, an inflammatory disease or an infection.

In typical embodiments, a library of cyclic polymers is made using themethods set forth above, and the cyclic polymers of the library are eachassayed for biological activity. Such assays are well known in the artand include cell-free assays and cellular assays.

In particular embodiments, the subject methods find use in screening forvariants of a known biologically active cyclic peptide that have animproved activity. In these embodiments, variants of a cyclic peptideknown to have a biological activity, e.g., a peptide havinganti-microbial (e.g., cyclic peptide inhibitors of beta(1,3)glucansynthesis (Tkacz et al. Curr Opin Microbiol. 2001 4:540-5) or cyclicpeptide antibiotics (e.g. Kohli et al. Nature. 2002 418:658-61; Tsuberyet al., Peptides. 2001 October; 22(10):1675-81), anti-cancer activity,(e.g., triostin A, Yang et al., Prep Biochem Biotechnol. 2002 32:381-91)or any other activity, e.g., anti-sepsis activity (Vallespi et al., IntImmunopharmacol. 2003 3:247-56), are synthesized by a machine, cyclizedusing the above-described methods, and assayed to determine if thevariant has an improved activity.

The subject methods find particular use in production of cyclicpolymers. In particular, the subject methods find particular use inproducing cyclic polymers (e.g., cyclic peptides) that are notgenetically encodable, using a cell-free system. For example, thesubject methods may be used to produce cyclic peptides havingnon-naturally occurring or non-encodable amino acids, or cyclic peptidesthat cannot be produced in a cell by any means. Since the subjectmethods are straightforward, highly efficient, scalable and result in aproduct that is already highly purified and not modified or contaminatedwith cellular materials, the methods find particular use in manufactureof cyclic polymers for clinical investigations, and for therapeuticuses. Cyclic polymers identified using any method may be produced usingthe methods described herein.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the present invention, and are not intended to limit thescope of what the inventors regard as their invention nor are theyintended to represent that the experiments below are all or the onlyexperiments performed.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe subject invention.

Example 1

The method outlined in example 1 relies on a series of chemical ligationsteps in which the two functional domains of an intein are successivelyligated to the flanking ends of a synthetically produced polymer. Theresulting intein, reconstituted so that it now contains a syntheticpolymer positioned within it's active site, is then capable ofenzymatically cyclizing the polymer. The chemical ligation stepsinvolved in the joining together of the two intein domains and thesynthetic polymer utilize the selective reaction of C-terminalthioesters with sulfhydryl-containing amino acids positioned on theN-terminus of the reacting partner. This chemical approach is used,step-wise, to first ligate the C-terminal domain of the SsB DnaB inteinto one end of a synthetic polymer and then used again to ligate theN-terminal domain of SsB DnaB to the remaining end. Each ligation stepinvolves the generation of two starting intermediates; one partnercontains a C-terminal thioester and the other reacting partner containsa N-terminal sulfhydryl-containing residue/amino acid. The individualsteps outlined in example 1 describe how each starting intermediate isfirst generated and then how these intermediates are reacted, in series,to obtain the final product. FIG. 3 shows a five step reaction that maybe used to cyclize a peptide containing three monomers of X.

FIG. 3A (Step 1) describes a method whereby the C-terminal domain of theSsB DnaB intein is produced in such a way that it contains a C-terminalthioester. Since proteins typically do not naturally terminate with thischemical entity, a combination of enzymatic and chemical modificationscan be used to generate the desired C-terminal thioester. In the exampledescribed here, a second, mutated intein (derived from the Mxe GyrAintein; colored green) is first placed downstream of the C-terminus ofthe SsB DnaB intein domain. The downstream Mxe GyrA intein catalyzes theformation of a stable thioester linkage at the junction site betweenitself and the upstream SsB DnaB intein domain. This thioester link isthen selectively cleaved by addition of the reducing agent MESNA,thereby liberating the SsB DnaB intein domain with a C-terminalthioester. This is the first of three components that are necessary forthe generating the final reconstituted intein capable of cyclizing asynthetic polymer.

FIG. 3B (Step 2) describes certain features of the second component, thesynthetic polymer, and the method by which it is ligated to the firstcomponent, the SsB DnaB intein C-terminal domain. The synthetic polymeris produced such that it possesses a sulfhydryl-containing amino acid(e.g. cysteine) at its N-terminus and a tri-protected resin-activatedthioester linkage attached to a solid phase support at it's C-terminus.Chemical ligation of the synthetic polymer to the SsB DnaB C-terminaldomain occurs via nucleophilic attack by the synthetic polymer'sN-terminal sulfhydryl group on the carbonyl group of the SsB DnaB'sC-terminal thioester. The resulting ligation intermediate subsequentlyundergoes a spontaneous S—N acyl rearrangement, converting the junctionbetween the SsB DnaB intein C-terminus and the synthetic polymer into apeptide bond. The resulting product is referred to as the two-componentintermediate.

FIG. 3C (Step 3). This two-component intermediate is prepared for thefinal ligation step by releasing the protecting moieties from the resinand thereby making it's thioester linkage chemically accessible. Thisdeprotection step, sometimes referred to as “activation”, is usuallytriggered by addition of an acid or base, depending on the specificresin chemistry present. Once activated, the thioester linkage can becleaved by reaction with the reducing agent MESNA, thereby generating aC-terminal thioester on the two-component intermediate.

FIG. 3D (Step 4). In a process analogous to that outlined in step one,reaction of the C-terminal thioester of the two-component intermediatewith the N-terminal sulfhydryl group of the third component (N-terminaldomain of the SsB DnaB intein) leads to a fully reconstituted inteincapable of cyclizing the synthetic polymer that has been ligated intoit's active site.

FIG. 3E (Step 5) Altering the reaction conditions appropriatelyfacilitates the intein catalyzed cyclization of the synthetic polymer.

It is evident from the above discussion that the subject inventionprovides an important new means for producing cyclic polymers, includingcyclic peptides having non-naturally occurring amino acids. As such, thesubject methods and systems find use in a variety of differentapplications, including research, medical, therapeutic and otherapplications, including drug screening. Accordingly, the presentinvention represents a significant contribution to the art.

What is claimed is:
 1. A method for making a cyclic polymer, comprising: incubating a compound of the structure: D₁-X_((n))-D₂ wherein D₁ is a first catalytic domain of an intein; wherein X_((n)) is a polymer comprising n residues of a monomer X, n is at least 2, the polymer is not genetically encodable and is not made by a cell, and the polymer has a first reactive site for said intein at its N-terminus; and wherein D₂ is a second catalytic domain of an intein, having at its N-terminus a second reactive site for said intein; under intein reaction conditions to produce said cyclic polymer.
 2. The method of claim 1, wherein said incubating includes changing the temperature of said compound.
 3. The method of claim 1, wherein said synthetic polymer comprises at least one non-naturally occurring monomer.
 4. The method of claim 1, wherein said synthetic polymer comprises at least one amino acid monomer.
 5. The method of claim 1, wherein said synthetic polymer comprises at least one nucleotide monomer.
 6. The compound of claim 1, wherein D₁, X_((n)), and D₂ are joined by peptide bonds.
 7. The compound of claim 1, wherein n is at least
 4. 8. The compound of claim 1, wherein said monomers are amino acid monomers.
 9. The compound of claim 1, wherein said monomers are nucleotide monomers. 